Articles with public access mandates - Alexia IasonosLearn more
Not available anywhere: 5
A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer
RA Cowan, AGZ Eriksson, SM Jaber, Q Zhou, A Iasonos, O Zivanovic, ...
Gynecologic Oncology 145 (2), 230-235, 2017
Mandates: US National Institutes of Health
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre …
JM Pagel, JD Soumerai, N Reddy, D Jagadeesh, A Stathis, A Asch, ...
The Lancet Oncology 23 (8), 1021-1030, 2022
Mandates: US National Institutes of Health, Lymphoma Research Foundation, USA
Extensive versus focal lymphovascular invasion in squamous cell carcinoma of the cervix: A comprehensive international, multicenter, retrospective clinicopathologic study
AM Praiss, D Allison, B Tessier-Cloutier, J Flynn, A Iasonos, L Hoang, ...
Gynecologic oncology 176, 147-154, 2023
Mandates: US National Institutes of Health
Germline pathogenic variants and genetic counseling by ancestry in patients with epithelial ovarian cancer
TY Sia, A Maio, YM Kemel, KS Arora, SB Gordhandas, RM Kahn, ...
JCO Precision Oncology 7, e2300137, 2023
Mandates: US National Institutes of Health
Evaluation of early phase dose finding algorithms in heterogeneous populations
M Clertant, A Iasonos, J O’Quigley
Journal of Statistical Planning and Inference 231, 106080, 2024
Mandates: Agence Nationale de la Recherche
Available somewhere: 169
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
E Basch, X Jia, G Heller, A Barz, L Sit, M Fruscione, M Appawu, A Iasonos, ...
JNCI: Journal of the National Cancer Institute 101 (23), 1624-1632, 2009
Mandates: US National Institutes of Health
Efficacy of MEK inhibition in patients with histiocytic neoplasms
EL Diamond, BH Durham, GA Ulaner, E Drill, J Buthorn, M Ki, L Bitner, ...
Nature 567 (7749), 521-524, 2019
Mandates: US National Institutes of Health
A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking …
RS Suidan, PT Ramirez, DM Sarasohn, JB Teitcher, S Mironov, RB Iyer, ...
Gynecologic oncology 134 (3), 455-461, 2014
Mandates: US National Institutes of Health
BRAF mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer
RN Grisham, G Iyer, K Garg, D DeLair, DM Hyman, Q Zhou, A Iasonos, ...
Cancer 119 (3), 548-554, 2013
Mandates: US National Institutes of Health
A comprehensive comparison of the continual reassessment method to the standard 3+ 3 dose escalation scheme in Phase I dose-finding studies
A Iasonos, AS Wilton, ER Riedel, VE Seshan, DR Spriggs
Clinical Trials 5 (5), 465-477, 2008
Mandates: US National Institutes of Health
A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma
O Zivanovic, LM Jacks, A Iasonos, MM Leitao Jr, RA Soslow, E Veras, ...
Cancer 118 (3), 660-669, 2012
Mandates: US National Institutes of Health
Renal cell carcinoma in young and old patients—is there a difference?
RH Thompson, MA Ordonez, A Iasonos, FP Secin, B Guillonneau, ...
The Journal of urology 180 (4), 1262-1266, 2008
Mandates: US National Institutes of Health
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on …
O Zivanovic, MM Leitao, A Iasonos, LM Jacks, Q Zhou, NR Abu-Rustum, ...
Journal of Clinical Oncology 27 (12), 2066-2072, 2009
Mandates: US National Institutes of Health
A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of …
J Carter, Y Sonoda, RE Baser, L Raviv, DS Chi, RR Barakat, A Iasonos, ...
Gynecologic oncology 119 (2), 358-365, 2010
Mandates: US National Institutes of Health
A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial …
RS Suidan, PT Ramirez, DM Sarasohn, JB Teitcher, RB Iyer, Q Zhou, ...
Gynecologic oncology 145 (1), 27-31, 2017
Mandates: US National Institutes of Health
Basket trials in oncology: a trade-off between complexity and efficiency
KM Cunanan, M Gonen, R Shen, DM Hyman, GJ Riely, CB Begg, ...
Journal of Clinical Oncology 35 (3), 271, 2017
Mandates: US National Institutes of Health
TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
EY Rosen, DA Goldman, JF Hechtman, R Benayed, AM Schram, E Cocco, ...
Clinical Cancer Research 26 (7), 1624-1632, 2020
Mandates: US National Institutes of Health
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center
JJ Mueller, QC Zhou, A Iasonos, RE O'Cearbhaill, FA Alvi, A El Haraki, ...
Gynecologic oncology 140 (3), 436-442, 2016
Mandates: US National Institutes of Health
Classification and regression tree (CART) analysis of endometrial carcinoma: seeing the forest for the trees
JN Barlin, Q Zhou, CMS Clair, A Iasonos, RA Soslow, KM Alektiar, ...
Gynecologic oncology 130 (3), 452-456, 2013
Mandates: US National Institutes of Health
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
CSM Diefenbach, S Gnjatic, P Sabbatini, C Aghajanian, ML Hensley, ...
Clinical Cancer Research 14 (9), 2740-2748, 2008
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program